Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Publications

Found 108 results
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is B  [Clear All Filters]
Journal Article
Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA.  2021.  Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 27(9):1443-1451.
Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M.  2021.  Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.. BMJ Open Gastroenterol. 8(1)
Cohen-Mekelburg S, Rosenblatt R, Gold S, Burakoff R, Waljee AK, Saini S, Schackman BR, Scherl E, Crawford C.  2018.  The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.. J Crohns Colitis. 12(9):1030-1035.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al..  2020.  Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al..  2020.  Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al..  2020.  Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.
Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW.  2012.  Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease.. PLoS One. 7(7):e41594.
Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al..  2014.  Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.
Yang A, Chen Y, Scherl E, Neugut AI, Bhagat G, Green PHR.  2005.  Inflammatory bowel disease in patients with celiac disease.. Inflamm Bowel Dis. 11(6):528-32.
Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V.  2019.  Innovations in Oral Therapies for Inflammatory Bowel Disease.. Drugs. 79(12):1321-1335.
Ma C, Sedano R, Almradi A, Casteele NVande, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R et al..  2021.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.. Gastroenterology. 160(7):2291-2302.
Ma C, Sedano R, Almradi A, Casteele NVande, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R et al..  2021.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.. Gastroenterology. 160(7):2291-2302.
Barba-Spaeth G, Longman RS, Albert ML, Rice CM.  2005.  Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.. J Exp Med. 202(9):1179-84.
Harris A, Eswaran S, Bosworth B, Gambarin-Gelwan M, Scherl EJ.  2007.  Mesalamine-induced Pneumonitis and Serum Sickness-like Reaction.. Gastroenterol Hepatol (N Y). 3(11):875-7.
Stathopoulos C, Jacquin-Becker C, Becker HD, Li T, Ambrogelly A, Longman R, Söll D.  2001.  Methanococcus jannaschii prolyl-cysteinyl-tRNA synthetase possesses overlapping amino acid binding sites.. Biochemistry. 40(1):46-52.
Diehl GE, Longman RS, Zhang J-X, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR.  2013.  Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.. Nature. 494(7435):116-20.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS.  2021.  No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.. Clin Gastroenterol Hepatol. 19(11):2312-2314.e3.
Stathopoulos C, Li T, Longman R, Vothknecht UC, Becker HD, Ibba M, Söll D.  2000.  One polypeptide with two aminoacyl-tRNA synthetase activities.. Science. 287(5452):479-82.
Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al..  2012.  Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.
Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al..  2012.  Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Battat R, Long MD.  2021.  Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data. Am J Gastroenterol. 116(10):2029-2031.